Holen Sie sich die Stockscreener-App
68.99
1.67%
-1.094
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$70.08
Offen:
$69.515
24-Stunden-Volumen:
2.56M
Relative Volume:
0.57
Marktkapitalisierung:
$213.87B
Einnahmen:
$54.98B
Nettoeinkommen (Verlust:
$7.77B
KGV:
27.71
EPS:
2.49
Netto-Cashflow:
$9.14B
1W Leistung:
-4.04%
1M Leistung:
-2.91%
6M Leistung:
+3.47%
1J Leistung:
-13.61%
1-Tages-Spanne:
$68.61
$69.72
1-Wochen-Bereich:
$68.61
$72.21
52-Wochen-Spanne:
$61.24
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Firmenname
Astrazeneca PLC
Sektor
Branche
Telefon
44 20 3749 5000
Adresse
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Vergleichen Sie AZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
68.96 | 219.57B | 54.98B | 7.77B | 9.14B | 2.49 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca PLC Aktie (AZN) Neueste Nachrichten
AstraZeneca’s New Study Sheds Light on COPD Burden in Egypt - TipRanks
AstraZeneca’s INTERSTELLAR Study: Real-World Insights into Anifrolumab for Lupus - TipRanks
AstraZeneca and Bayer’s Collaborative Study on Metastatic Prostate Cancer: A Potential Game-Changer? - TipRanks
AstraZeneca’s Benralizumab Study: A Potential Game-Changer for Severe Asthma - TipRanks
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies - Zacks Investment Research
AstraZeneca’s OPTIMISE-CKD Study: A Closer Look at Chronic Kidney Disease Management in Spain - TipRanks
AstraZeneca’s Real-Life Study on Benralizumab: Market Implications and Progress - The Globe and Mail
AstraZeneca’s AI-Driven Breast Cancer Risk Study: A New Frontier in Personalized Medicine - TipRanks
AstraZeneca’s Dapagliflozin Study: A New Hope for Chronic Kidney Disease in China - TipRanks
AstraZeneca’s Groundbreaking Study on KRASG12D Mutation: A Potential Game-Changer in Cancer Treatment - TipRanks
AstraZeneca’s Real-World Study on Olaparib for Prostate Cancer: Key Insights for Investors - TipRanks
AstraZeneca Completes Phase II Asthma Study: Market Implications and Insights - TipRanks
AstraZeneca’s Phase III Study on Benralizumab: A Potential Game-Changer for Pediatric Asthma - TipRanks
AstraZeneca, Daiichi Sankyo get U.S. breakthrough therapy status (AZN:NASDAQ) - Seeking Alpha
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update - GlobeNewswire Inc.
AstraZeneca Loses Bid To Revive Patent For Diabetes Drug - Law360
JPMorgan Goes Global With HOLA ETF—Stocks Plus Built‑In Crash Protection - Benzinga
AstraZeneca’s SERENA-6 Trial: A Potential Game-Changer in Breast Cancer Treatment - TipRanks
AstraZeneca’s New CAR T Therapy Study: A Potential Game-Changer for Refractory SLE - TipRanks
AstraZeneca’s Phase 3 COPD Study: Key Insights for Investors - TipRanks
AstraZeneca’s Promising Phase II Study on AZD7798 for Crohn’s Disease - TipRanks
AstraZeneca’s Benralizumab Trial: A Potential Game-Changer for Pediatric Eosinophilic Diseases - TipRanks
AstraZeneca’s New Study on AZD4954: A Potential Game Changer in Cardiovascular Treatment - TipRanks
AstraZeneca’s Ravulizumab Study: A New Hope for gMG Patients - TipRanks
AstraZeneca rare disease drug fails key trial tests - BioPharma Dive
AstraZeneca’s AZD5004 Study: A New Hope for Type 2 Diabetes Treatment? - TipRanks
AstraZeneca’s Real-World Study on Dapagliflozin: A Potential Game-Changer for Heart Failure Treatment - TipRanks
AstraZeneca’s TROPION-Lung15 Study: A New Hope for Advanced Lung Cancer? - TipRanks
AstraZeneca’s New Obesity Drug: A Potential Game-Changer? - TipRanks
AstraZeneca’s CASPIAN Study: Promising Advances in Lung Cancer Treatment - TipRanks
AstraZeneca’s New Study Targets COPD Burden in Egypt: What Investors Need to Know - The Globe and Mail
AstraZeneca’s Amyloidosis Drug Fails In Phase III But Subgroup Hopes Persist - insights.citeline.com
AstraZeneca reports Phase III trial of anselamimab did not meet primary goal - Investing.com India
AstraZeneca therapy for clearing protein deposits fails main goal in late-stage study - MarketScreener
AstraZeneca’s anselamimab treatment fails to meet main trial goal; shares slip - Investing.com UK
AstraZeneca shares open lower after rare disease drug fails to meet main trial goal - Proactive Investors
AstraZeneca Rare Disease Drug Disappoints in Advanced Study - Bloomberg.com
AstraZeneca's amyloidosis treatment fails main goal in late-stage study - MarketScreener
AstraZeneca drug fails main goal of late-stage amyloidosis study - Reuters
AstraZeneca: mixed phase III trial results for anselamimab - MarketScreener
AstraZeneca Says Phase 3 Trial for Amyloidosis Medication Fails to Meet Primary Endpoint - MarketScreener
AstraZeneca’s Real-world COPD Study: Market Implications of BGF Analysis - TipRanks
AstraZeneca’s INTERSTELLAR Study: Real-World Insights into Anifrolumab for SLE - TipRanks
Cancer drugmaker LaNova to sell to China’s Sino Biopharm - BioPharma Dive
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
AstraZeneca PLC (AZN) Secures EU Approval for Imfinzi - Insider Monkey
AstraZeneca Meets All Key Goals in Phase III Hypertension Study - Nasdaq
AstraZeneca’s Observational Study on SLE in Russia: Key Insights for Investors - TipRanks
Barclays: AstraZeneca's Q2 Results to Demonstrate 'Resilience' Amid Headwinds - MarketScreener
AstraZeneca’s Phase III Study on Baxdrostat and Dapagliflozin: A Potential Breakthrough in CKD Treatment - TipRanks
AstraZeneca (LSE:AZN) Unveils Promising Phase III Results For Baxdrostat In Hypertension Trial - Yahoo Finance
Finanzdaten der Astrazeneca PLC-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):